Cytokinetics has revealed the results from a phase 3 trial of its hypertrophic cardiomyopathy (HCM) drug aficamten that it hopes will allow it to compete with Bristol-Myers Squibb’s first-to-market ...
Bristol-Myers Squibb has new data backing up the value of mavacamten for obstructive hypertrophic cardiomyopathy (HCM), as it waits for a delayed verdict on its marketing application for the drug, ...
Italy closes probe into DeepSeek after commitments to warn of AI 'hallucination' risks Italy’s antitrust authority has ended an investigation into the Chinese AI system DeepSeek for allegedly failing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback